Short CV/Education and training

  • Since 2019
    Full professor in Immunology, head of the department of Tumor Immunology at the Radboud Institute for Molecular Life Sciences (Currently supervising 8 technicians, 17 AGIKOs/PhD students, 3 post-docs.), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  • 2011 – 2019
    Professor Translational Tumor Immunology, Department of Tumor Immunology 0.75 fte and Medical Oncology 0.25 fte, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  • 2009 – 2011
    Senior lecturer, Department of Tumor Immunology 0.75 fte and Medical Oncology 0.25 fte, Nijmegen Centre for Molecular Life Sciences (Supervision 8 technicians, 4 AGIKOs/PhD students, 4 post-docs.), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

  • 2004 – 2009
    Staff member Department of Tumor Immunology, 0.5 fte tenured; Department of Pediatric Hemato-oncology 0.5 fte fixed term, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Supervision 6 technicians, 4 AGIKOs/PhD students, 4 post-docs.

  • 1997 – 2004
    Post-doc, 1 fte, fixed term, Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Supervision 2-4 technicians, 2-3 AGIKOs/PhD students, 2-3 post-docs.

  • 1993 – 1994
    Visiting Scientist, Department of Hematology, University Hospital Zurich, Zurich, Switzerland.

  • 1991 – 1997
    PhD project, 1 fte, fixed term, Department of Dermatology, University Medical Center Utrecht, The Netherlands. Supervision 1 technician.

  • 1990 – 1991
    Researcher, 1 fte, tenured term, Swiss Institute for Allergy and Asthma research, Davos, Switzerland

Selected publications

  • Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 2013. 121(3): 459-67.

  • Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? The lancet oncology, 2012. 13(1): e32-42.

  • Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 2012. 119(10): 2284-92.

  • Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood, 2012. 120(19): 3936-44.

  • Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH, van Krieken JH, Adema GJ, Figdor CG, de Vries IJ. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. The Journal of clinical investigation, 2011. 121(8): 3100-8.

  • Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJ. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010. 116(4): 564-74.

  • Srinivas M, Aarntzen EH, Bulte JW, Oyen WJ, Heerschap A, de Vries IJ, Figdor CG. Imaging of cellular therapies. Adv Drug Deliv Rev, 2010. 62(11): 1080-93.

  • Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, Adema GJ. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood, 2008. 111(8): 4245-53.

  • Benitez-Ribas D, Adema GJ, Winkels G, Klasen IS, Punt CJ, Figdor CG, de Vries IJ. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med, 2006. 203(7): 1629-35.

  • Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood, 2005. 106(4): 1278-85.


Selected projects

  • TDAR-on-a-chip: a human in vitro HTS TDAR assay platform. Crack-it Challenge. Principal Investigator: IJM de Vries, Mimetas, ImmunXperts

  • Effects of Human Milk Oligosaccharides in infant and adult nutrition and immune health. Health Holland, Friesland Campina. Principal Investigator: IJM de Vries, V Triantis HH Nutricia

  • tolDC therapy for rheumatoid arthritis. Principal Inverstigator: ZonMW, SGF, Health Holland consortium, IJM de Vries

  • Optimizing the design of dendritic cell vaccine immunotherapies. ZonMW. Principal Investigator: IJM de Vries, G. vd Bogaart, S. van Kasteren

  • KIKA 359: Dendritic cell vaccines to prevent cancer in Constitutional Mismatch Repair Deficiency (CMMR-D) syndrome. Principal Investigator: G Schreibelt, MCJ Jongmans, IJM de Vries, N Hoogerbrugge

  • KWF 12413: Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients. Principal Investigator: IJM de Vries, PB Ottevanger

  • ONCOBIOME, Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response. H2020-SC1-2018-825410. Principal Investigator: EU consortium, IJM de Vries

  • KWF 11618: Galectin-9 is required for dendritic cell function during anti-melanoma immunity. Principal Investigator: IJM de Vries, AB van Spriel

  • DC4Balance, Dendritic Cell Targeting for Resetting Immune Balance. Health-Holland, Top Sector Life Sciences & Health. Principal Investigator: Consortium, IJM de Vries

  • KWF 10673: Towards prediction of the outcome of cancer immunotherapy. Principal Investigator: CG Figdor, IJM de Vries

  • PRECIOUS, Scaling-up immunomodulating nanomedicines for multimodal precision cancer immunotherapy EU H2020 (coordinator)

  • NWO-ZonMw 2016, Vaccinaties met autologe, natuurlijk circulerende dendritische cellen (nDC) beladen met synthetische peptides bij patiënten met maligne melanoom stadium IIIb en IIIc: evaluatie van klinische respons, kwaliteit van leven en economische aspecten. Principal Investigator: IJM de Vries

  • Dendritic cell therapy part of the Dutch Health Care system (Voorwaardelijke toelating basispakket), to carry out a large randomized study with natural dendritic cell vaccines.

  • PROCROP, Professional cross-priming dendritic cells for ovary and prostate cancer H2020-PHC-2014-two-stage- 635122. Principal Investigator: EU consortium, IJM de Vries

  • ATK, Stichting afweer tegen kanker: Natural dendritic cells for immunotherapy of chemo-naive metastatic castration-resistant prostate cancer patients. Principal Investigator: IJM de Vries, H. Westdorp, F Witjes, W Gerritsen

  • KWF 2013-6430: GMP production of PLGA beads for in vivo cell tracking. Principal Investigator: IJM de Vries, ML Zandvliet, CG Figdor

  • NWO Vici: Theranostics for the development of successful natural dendritic cell vaccines to combat and prevent cancer. Principal Investigator: IJM de Vries

  • Radboudumc JO project 2013: Multifunctional Fight against Cancer. Supervisors: IJM de Vries, J Jacobs

  • Swedish Research Society 2013: Dissecting mechanisms exploited by plasmacytoid dendritic cells for antitumor immunity in therapeutically vaccinated prostate cancer patients. Supervisors: IJM de Vries, R. Kiessling

  • RIO JO project 2013: Dissecting mechanisms exploited by plasmacytoid dendritic cells for antitumor immunity in prostate cancer patients. Principal Investigator: IJM de Vries, W. Gerritsen

  • NWO-ZonMW 2012:pTO 95103002: Natural circulating plasmacytoid dendritic cells: Key for antitumor immunity? Principal Investigator: IJM de Vries

  • BetaTrain: European Training Network for Excellence in Molecular Imaging in Diabetes, EC FP7 ITN.

  • KWF 2010-4722: Vaccination of early-stage high-risk uveal melanoma patients with mRNA-transfected dendritic cells. Principal investigators: IJM de Vries, CJA Punt, ADA Paridaens.

  • KWF 2006-3699: Toll like receptor-mediated dendritic cell maturation: The key towards induction of potent anti-tumor immunity? Principal investigators: IJM de Vries, GJ Adema, CJA Punt.

  • NWO Vidi: Dendritic Cells en route. Principal investigator: IJM de Vries.

  • NWO Aspasia. Principal investigator: IJM de Vries.

  • ENCITE, European Network for Cell Imaging and Tracking Expertise, EC FP7 project.

  • Pharmachild, Long-term PHARMacovigilance for adverse effects in childhood arthritis focusing on immune modulatory drugs, EC FP7 project.

  • NWO-ZonMW 2008: pTO 95100106: Boosting the immune response to prevent cancer: Frameshift neopeptide-derived antigens as novel tumor specific targets for immune therapy in hereditary colorectal cancer. Principal investigators: IJM de Vries, N. Hoogerbrugge.

  • KWF 2009-4580: NPK project translational research.

  • Van der Es foundation 222, 2010: STAT6 en platinum-chemotherapie gevoeligheid. Principal investigators: WJ Lesterhuis, CJA Punt, IJM de Vries.

Patents

  • Composition and methods for generating an immune response in a subject

  • Peptides for use in the immunotherapy of renal cell carcinoma

Membership in scientific bodies/juries

  • Elected research member of the Academia Europaea (2021-present)

  • Elected council member of the International Union of Immunological Societies (IUIS)(2020-present)

  • European Society of Molecular Imaging, TOPIM 2020 committee member

  • President NVVI – Dutch Society for Immunology (2018-present)

  • European Society of Molecular Imaging (ESMI) elected board member (2018-present)

  • European Society of Molecular Imaging, fouding member and chair of Immune Oncology & Therapy study Group (2017-2020)

  • Ambassador Board topX – a unique platform for women in Life Science (2020- present)

  • Member Research Council Panel Norway (2018, 2019, 2020)

  • Panel member in the domain of Biomedical Sciences of the Free University Brussels (VUB) Strategic Research Programs

  • Panel Member in the evaluation of the 2016 ERC consolidator grants (2016)

  • Elected member of the European Academy for Tumor Immunology (EATI) (since 2016)

  • Chair of the Scientific Evaluation Committee of “The ERA-NET TRANSCAN-2” (European Research Area Network: Aligning national/regional translational cancer research programmes and activities) Joint Transnational Call for proposals (15 funding organisations from 11 countries) (2015-2016)

  • Member of the program committee & poster discussant at ESMO Symposium on Immuno-Oncology (2015)

  • Organizer of the European Molecular Imaging meeting of the European Society for Molecular Imaging (2015)

  • Project advisor 1Valve (2014)

  • Board member of patient organization Patientenstem.nu (2015-present)

  • Board member of patient organization Inspire2Live (2014-2015), since 2015 scientific advisor

  • Member of the program committee of the yearly NVVI Wintermeeting (1/2014- present)

  • Member of the translational and applied research council of the Dutch Cancer Foundation (2013- 2019)

  • Member of the educational taskforce “Revision of the curriculum for the bachelor degree in biomedical sciences in Nijmegen” (2013-2014)

  • Member of the user committee (gebruikerscommissie) of project 95103005 entitled " Minor H antigen UTA2-1-loaded DC dendritic cells (DC)as vaccines to improve the therapeutic effect of donor lymphocyte infusions in B cell malignancies" PI Tuna Mutis, UMC Utrecht (2013-2015)

  • Organizer of ENCITE workshops ‘ Imagine Cancer: from Models to Patients’, Nijmegen (the Netherlands), 1/2012

  • Member of the training and supervision plan committee of the clinical institutes of RUN-MC

  • Member of the management team NCMLS, since 01/2011

  • Organizer of the 2010 edition of the Dutch Tumor Immunology Meeting (Breukelen, The Netherlands, 06/2011)

  • Organizer of the 2010 edition of the Dutch Tumor Immunology Meeting (Breukelen, The Netherlands, 06/2010)

  • Site visit of the research cancer center headed by Jean Jacques Fournié in Toulouse (France). On behalf of the French National Agency for Research Evaluation (AERES), November 19-20, 2009

  • Application for CCMO permission to perform clinical trials

  • Organizer of the 2009 edition of the Dutch Tumor Immunology Meeting (Breukelen, The Netherlands, 06/2009)

  • Co-organizer of N4I science day 2009, 2010,2011

  • Member of the NCMLS seminar committee, 11/2009 – 5/2011

  • Organizer of the 2008 edition of the Dutch Tumor Immunology Meeting (Breukelen, The Netherlands, 06/2008)

  • Co-organizer of the conference DC2003 (Amsterdam, The Netherlands)

Contact

You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here

Testimonials

  1. Read what our members say about AcademiaNet.

Follow us

Similar profiles

  1. Prof. Dr. Katrin Amunts

    Health, Brain research

  2. Prof. Dr. Silvia Arber

    Biological and related sciences, Health, Neuroscience

  3. Dr. Nicola Allen

    Health, Role of astrocytes in brain function

  4. Prof. Dr. Myriam Aouadi

    Health, Obesity, Diabetes, Immunology

 
 
Academia Net